I believe it's a clear case of regulatory capture. It's a regime that was designed in partnership with pharmaceutical firms, which ensured they would be able to set up all kinds of administrative impediments to make things extremely complex.
Don't forget that in 2011, Canada passed an act to reform the Canadian Access to Medicines Regime. A parliamentary majority voted to eliminate some of the administrative impediments, but then elections were triggered and the Senate had not yet adopted the bill, which meant it was was now dead on the Order Paper.
Everyone in Canada working in the field of intellectual property is well aware of the fact that the Canadian Access to Medicines Regime doesn't work. On top of everything else, right in the middle of the COVID‑19 pandemic, Canada refused to amend schedule 1 of the Patent Act to allow technologies used to combat COVID‑19 to be included among those that could be made available if a country were to have a go at getting around all the administrative roadblocks to try and obtain them.
That, in the end, is what Bolivia did, but Canada refused to help that country by amending the basket of treatments, medicines and vaccines available during pandemics and health emergencies.